C
Changxuan You
Researcher at Southern Medical University
Publications - 9
Citations - 4224
Changxuan You is an academic researcher from Southern Medical University. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 5, co-authored 6 publications receiving 3770 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Ji Feng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lin Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +21 more
TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
Journal ArticleDOI
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Gongyan Chen,Ji Feng Feng,Caicun Zhou,Yi-Long Wu,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lei Zhang,C.-P. Hu,Chengping Hu,Y. Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yuling Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC and updated PFS analyses from this study are described.
Journal ArticleDOI
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
Xingsheng Hu,Baohui Han,Aiqin Gu,Yiping Zhang,Shunchang Jiao,Chang li Wang,Jintao He,Xueke Jia,Li Zhang,Jiewen Peng,Meina Wu,Kejing Ying,Junye Wang,K. Ma,Shucai Zhang,Changxuan You,Fenlai Tan,Yinxiang Wang,Lieming Ding,Yan Sun +19 more
TL;DR: The data from over 6000 patients was consistent with the results of the ICOGEN study, and Icotinib demonstrated a favorable toxicity profile and efficacy in the routine clinical setting.
Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Cai-cun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Song-Wen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian-An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more